Zymergen's workforce strategy from 2020 to 2026 has been characterized by a dramatic and sustained contraction, indicative of profound operational challenges and strategic realignments. The company initiated a severe cost-cutting plan in August 2021, significantly reducing its workforce from 220 employees following problems with its first product, Hyaline, and the discontinuation of consumer care and electronics film programs. This trend of ongoing job cuts persisted, shrinking the headcount to 80 by October 2021, a period also marked by a co-founder's departure. While a temporary stabilization saw the workforce rebound to 120 by October 2022, this was explicitly part of continued restructuring and cost-cutting efforts. The overarching rationale for these strategic adjustments centered on mitigating severe financial pressures and streamlining operations through the discontinuation of non-performing product segments. The subsequent drastic reduction to merely 4 employees by January 2024 underscores a near-complete operational pivot or integration, reflecting a significant alignment with broader general biotech industry trends and the culmination of its extensive restructuring.